Mabwell (Shanghai) Bioscience Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2017-05-12
- Employees
- 1.4K
- Market Cap
- -
- Website
- https://www.mabwell.com
Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06389942
- Locations
- 🇨🇳
PKUcare Luzhong Hospital, Zibo, Shandong, China
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Phase 3
Recruiting
- Conditions
- Advanced Urothelial Carcinoma
- Interventions
- Drug: Chemotherapy
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 432
- Registration Number
- NCT06196736
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).
Phase 1
Active, not recruiting
- Conditions
- Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06175351
- Locations
- 🇨🇳
Baogang Hospital (No 3 Hospital Affiliated to Medical College of Inner Mongolia), Baotou, China
🇨🇳China-Japan Friendship Hospital, Beijing, China
🇨🇳Peking University Shougang Hospital, Beijing, China
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
Phase 1
Not yet recruiting
- Conditions
- Advanced Urothelial Carcinoma
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06079112
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: 7MW3711 for injection
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 281
- Registration Number
- NCT06008366
- Locations
- 🇨🇳
Ethics Committee of Fudan University Shanghai Cancer Center, Shanghai, 上海市, China
A Study of 7MW3711 in Subjects With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: 7MW3711 for injection
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 164
- Registration Number
- NCT06008379
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The Lung Cancer Center of Shanghai Chest Hospital, Shanghai, Shanghai, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 261
- Registration Number
- NCT05990452
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Centel, Shanghai, China
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects
Phase 1
Recruiting
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Drug: 9MW3811 InjectionDrug: Placebo
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05912049
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Malignant Solid Tumor
- Interventions
- Drug: 9MW3811 Injection
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 27
- Registration Number
- NCT05911984
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
An Evaluation of 9MW1911 Injection in Healthy Subjects
Phase 1
Active, not recruiting
- Conditions
- AsthmaAtopic DermatitisCOPD
- Interventions
- Drug: Experimental drug 9MW1911Drug: Placebo
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05803902
- Locations
- 🇨🇳
Peking Union Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath